Medical Enquiry

A Conditional Registration of Pharmaceutical Products during Disaster has been granted in Malaysia for the product PAXLOVID™ (PF-07321332 150mg film-coated tablets and ritonavir 100mg film-coated tablets) for the treatment of COVID-19 in adults who do not require supplemental oxygen and who are at increased risk for progression to severe COVID-19.

To report a suspected adverse event or side effect related to PAXLOVID™ (PF-07321332/ritonavir), please contact us via the following:

Email: [email protected]

* = Mandatory Fields